Nutex Health Inc (NUTX) valuation
Nutex Health P/E ratio history
Nutex Health trades at 7.7 times its earnings over the last twelve months and 7.3 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $164.62 | $10.48 | 15.7 | 18.1 |
| Dec 31, 2024 | $31.69 | $9.25 | 3.4 | — |
| Dec 31, 2023 | $27.00 | -$10.71 | n/m | — |
| Dec 31, 2022 | $285.00 | -$94.50 | n/m | — |
| Dec 31, 2021 | $618.00 | — | n/m | — |
| Dec 31, 2020 | $202.50 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Nutex Health valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Agilon HealthAGL | $1.42B | — | 77.3 | 0.2 |
| OmerosOMER | $1.33B | 10.7 | — | 34.8 |
| ConmedCNMD | $1.33B | 18.3 | 9.4 | 1.0 |
| Eton PharmaceutcialsETON | $1.43B | 133.8 | 26.4 | 13.5 |
| Pacira BiosciencesPCRX | $1.43B | 101.1 | 11.5 | 1.9 |
| Tandem Diabetes CareTNDM | $1.31B | — | — | 1.3 |
| Pennant GroupPNTG | $1.45B | 45.8 | 27.9 | 1.3 |
| Peer median | 45.8 | 19.0 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NUTX financials · NUTX returns
No forecast, no recommendation. This page describes Nutex Health Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.